AACR: Lung Cancer Vaccine Prolongs Survival
According to a report in USN, a small phase 2 trial for lung cancer vaccine seems to prolong life in patients with non-progressive non-small cell lung cancer (NSCLC). Belagenpumatucel – L (Lucanix), a therapeutic vaccine extended the five-year survival rate of patients up to 50% in moderately advanced lung cancer.
- 75 patients with stage 2, 3A, 3B, or 4 of lung cancer took part in the study.
- They were randomly assigned to various doses of vaccine derived from 4 lung cancer cell lines.
- On an average, patients survived for 14.5 months and five year survival rate was 20%.
- Patients with 3B and 4 stages of lung cancer and administered highest doses of vaccine survived for an average of 15.9 months.
- In these patients,
- One year survival rate was 61%
- Two year survival rate was 41%
- Five year survival rate was 18%
- However, after chemotherapy, patients with 3B and 4 stage of non progressive NSCLC and had been vaccinated, showed an average survival of 44.4 months and five year survival rate of 50%.
- Patients, in whom the disease progressed after chemotherapy, survived for 14 months with a 9% five year survival rate.
- Phase 3 trials to confirm the results are underway in eight countries.
The researchers, Lyudmila Bazhenova, M.D., et al, are excited since such rates of prolonged survival are unheard of in NSCLC.
The study findings have been presented at annual meeting of the American Association for Cancer Research, held between March 31 and April 4, in Chicago.